Sung‐Bae Kim
Impact in
- Oncology top 0.1%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Cancer Research top 0.5%
- Breast Cancer Treatment Studies
Papers in
- Oncology 178
- HER2/EGFR in Cancer Research 63
- Cancer Treatment and Pharmacology 60
- Cancer Immunotherapy and Biomarkers 33
-
- Advanced Breast Cancer Therapies 58
- Co-authors
- Javier Cortés (28 shared papers)Emma Clark (5 shared papers)Mark Benyunes (4 shared papers)Sandra M. Swain (4 shared papers)Graham Ross (4 shared papers)Jean-Marc Ferrero (5 shared papers)Jungsil Ro (17 shared papers)Seock‐Ah Im (56 shared papers)
- Journals
- Journal of Clinical Oncology (85 papers)Cancer Research and Treatment (22 papers)Cancer Research (21 papers)Breast Cancer Research and Treatment (13 papers)European Journal of Cancer (12 papers)
- Partner nations
- South KoreaUnited StatesSpain
In The Last Decade
Sung‐Bae Kim
415 papers receiving 17.1k citations
Sung‐Bae Kim's Hit Papers
Peers
Comparison fields: 5 of 155
- Oncology 8.1k
- Cancer Research 2.0k
- Pulmonary and Respiratory Medicine 3.8k
- Radiology, Nuclear Medicine and Imaging 2.4k
- Otorhinolaryngology 441
Countries citing papers authored by Sung‐Bae Kim
This map shows the geographic impact of Sung‐Bae Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sung‐Bae Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sung‐Bae Kim more than expected).
Fields of papers citing papers by Sung‐Bae Kim
This network shows the impact of papers produced by Sung‐Bae Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sung‐Bae Kim. The network helps show where Sung‐Bae Kim may publish in the future.
Co-authors
The 25 scholars most cited alongside Sung‐Bae Kim, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 442 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer Hit paper breakdown → | 2011 | 1789 |
| 2 | Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer Hit paper breakdown → | 2015 | 1453 |
| 3 | Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer Hit paper breakdown → | 2015 | 1439 |
| 4 | Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial Hit paper breakdown → | 2019 | 786 |
| 5 | Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study Hit paper breakdown → | 2013 | 705 |
| 6 | Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2014 | 516 |
| 7 | 2007 | 408 | |
| 8 | Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial Hit paper breakdown → | 2017 | 377 |
| 9 | Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus Hit paper breakdown → | 2018 | 365 |
| 10 | 2013 | 361 | |
| 11 | 2006 | 293 | |
| 12 | 2020 | 292 | |
| 13 | 2012 | 261 | |
| 14 | 2016 | 221 | |
| 15 | 2020 | 176 | |
| 16 | 2000 | 162 | |
| 17 | 2019 | 157 | |
| 18 | 2007 | 128 | |
| 19 | 2018 | 123 | |
| 20 | 2013 | 120 |
About Sung‐Bae Kim
Sung‐Bae Kim is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Cancer Research and Molecular Biology, having authored 442 papers that have together received 17.5k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (63 papers), Cancer Treatment and Pharmacology (60 papers), Advanced Breast Cancer Therapies (58 papers), Breast Cancer Treatment Studies (48 papers), Esophageal Cancer Research and Treatment (44 papers), Cancer Immunotherapy and Biomarkers (33 papers), Head and Neck Cancer Studies (31 papers) and Structural Behavior of Reinforced Concrete (21 papers). The work is most often cited by research in Oncology (8.1k citations), Cancer Research (2.0k citations), Pulmonary and Respiratory Medicine (3.8k citations), Radiology, Nuclear Medicine and Imaging (2.4k citations) and Otorhinolaryngology (441 citations). Sung‐Bae Kim has collaborated with scholars based in South Korea, United States and Spain. Frequent co-authors include Javier Cortés, Emma Clark, Mark Benyunes, Sandra M. Swain, Graham Ross, Jean-Marc Ferrero, Jungsil Ro, Seock‐Ah Im, Adam Knott and Andreas Schneeweiß. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and Treatment, Cancer Research, Breast Cancer Research and Treatment and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.